Event Date/Time: Jun 23, 2011
End Date/Time: Jun 23, 2011
To help ensure medicines for children was a part of the mainstream drug development process, and not just an optional extra, the European Commission introduced Paediatric Investigation Plans (PIPs). This will lead to children benefitting from better treatments and pharmaceutical companies will be rewarded as a result of the additional effort and costs of paediatric drug development. SMiâ€™s Masterclass addresses the problems faced during the creation of a PIP, and analyses ways to overcome common challenges ahead.